glp-1 receptor agonist with dpp-4 inhibitor combination not recommended The Role of Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect dpp-4_inhibitors [TUSOM | Pharmwiki]

doi: 10.1111/dom.13487

The other currently available once-weekly GLP-1 agonists in the US Astra Zenecas Bydureon (exenatide) and GSKs Tanzeum (albiglutide) require a reconstitution process that takes time to prepare before use

The ACC document, which was endorsed by the American Diabetes Association (ADA), outlined a variety of considerations for use of these agents in patients with ASCVD, including considerations that may warrant selection of either a GLP-1 RA or an SGLT-2 inhibitor for cardiovascular risk reduction ( Table 1 )

Liraglutide attenuates myocardial fibrosis via inhibition of AT1R-Mediated ROS production in hypertensive mice

Endocr Pract 2018